Mode
Text Size
Log in / Sign up
N/A N=50 Randomized Treatment

Oral Nifedipine Versus Oral Labetalol

Severe Postpartum Hypertension

Enrolled (actual)
50
Serious AEs
0.0%
Results posted
Dec 2017
Primary outcome: Primary: Time (Hours) to Attain Sustained Blood Pressure Goal After Treatment Initiated With Antihypertensive Medication — 37.6; 38.2 hours

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Labetalol (Drug); Nifedipine (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
Female
Sponsor
Cedars-Sinai Medical Center
Primary completion
Jun 2015

Outcome Measures

OutcomeResultp-value
PRIMARY
Time (Hours) to Attain Sustained Blood Pressure Goal After Treatment Initiated With Antihypertensive Medication
37.6; 38.2
SECONDARY
Total Length of Hospital Stay in Days
4.0; 4.3

Summary

This study's aim is to determine whether oral extended release nifedipine is superior to oral labetolol for the management of postpartum severe hypertension, specifically time to achieve goal blood pressure, and shortening hospital stay. Our hypothesis is that oral extended release nifedipine is superior to oral labetolol for achieving goal blood pressure in the postpartum period.

Eligibility Criteria

Inclusion Criteria

  • Age ≥ 18 years with the abililty to give informed consent
  • Intrauterine pregnancy ≥ 32 weeks
  • Postpartum
  • Persistent postpartum blood pressures ≥ 160/105 on two or more occasions
  • Primary obstetrician amenable to starting either study medication in the postpartum period

Exclusion Criteria

  • Use of other oral antihypertensives concomitantly
  • Known AV heart block
  • HR 120
  • Absolute contraindication to nifedipine or labetolol such as allergy
  • Significant renal disease (Cr >1.5 mg/dL)
  • Heart failure
  • Moderate persistent or severe asthma
  • Preexisting diagnosis of chronic hypertension with medical treatment before delivery
  • Chronic hypertension
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02168309). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search